Voyager Therapeutics, Inc. (VYGR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue (including from related parties, see note 12) | 5,200 | 6,473 | 24,629 | 29,578 |
| Research and development | 31,330 | 31,526 | 30,241 | 34,452 |
| General and administrative | 10,495 | 9,640 | 8,168 | 10,151 |
| Total operating expenses | 41,825 | 41,166 | 38,409 | 44,603 |
| Operating loss | -36,625 | -34,693 | -13,780 | -15,025 |
| Other income | 427 | 418 | 200 | 20 |
| Interest income | 2,831 | 3,291 | 4,579 | 4,888 |
| Total other income, net | 3,258 | 3,709 | 4,779 | 4,908 |
| Loss before income taxes | -33,367 | -30,984 | -9,001 | -10,117 |
| Income tax provision | 15 | 37 | 43 | 24 |
| Net loss | -33,382 | -31,021 | -9,044 | -10,141 |
| Net unrealized (loss) gain on available-for-sale securities | -22 | 208 | 489 | -16 |
| Total other comprehensive (loss) income | -22 | 208 | 489 | -16 |
| Comprehensive loss | -33,404 | -30,813 | -8,555 | -10,157 |
| Earnings per share, basic | -0.57 | -0.53 | -0.16 | -0.18 |
| Earnings per share, diluted | -0.57 | -0.53 | -0.16 | -0.18 |
| Weighted average number of shares outstanding, basic | 58,666,460 | 58,349,769 | 57,851,110 | 57,721,934 |
| Weighted average number of shares outstanding, diluted | 58,666,460 | 58,349,769 | 57,851,110 | 57,721,934 |